Clinical Trials

CUP (carcinoma of unknown primary syndrome)

Recruitment stopped
Ongoing Recruitment


(second-line, BRCAness)
Title:A Randomized Phase-2 Study of Trabectedin/Olaparib Compared to Physician's Choice in Subjects With Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies
Indication:DNA Repair-Deficiency Disorders
Type of study:Phase II
Contact: Barbara Stöhr (Study Nurse)
Investigator: Prof. Dr. Stefan Fröhling (Leiter klinische Prüfung)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" ( registriert. Siehe NCT03127215
EudraCT: 2017-001755-31 (siehe EU klinisches Studienregister)